---
schema_version: "secwatch.filing_event.v1"
accession: "0000200406-25-000170"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2025-07-16T23:59:59+00:00"
generated_at: "2026-05-18T06:20:19.427828+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# JNJ Q2 sales $23.7B (+5.8%); GAAP EPS $2.29 (+18.7%); adj. EPS $2.77 (-1.8%)

## Summary
- Q2 sales $23,743M (+5.8% YoY); U.S. $13,544M (+7.8%), International $10,199M (+3.2%).
- GAAP net earnings $5,537M; diluted EPS $2.29 vs $1.93 a year ago (+18.7%).
- Adjusted net earnings $6,699M; adjusted diluted EPS $2.77 vs $2.82 (-1.8%).
- Innovative Medicine sales $15,202M (+4.9%); MedTech sales $8,541M (+7.3%).
- Gross margin 67.9% vs 69.4% year ago; R&D expense $3,516M (14.8% of sales).

## SEC filing metadata
- accession: 0000200406-25-000170
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2025-07-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000020040625000170/0000200406-25-000170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000020040625000170/jnj-20250716.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000200406-25-000170
- JSON: https://secwatch.observer/filing/0000200406-25-000170.json
- Plain text: https://secwatch.observer/filing/0000200406-25-000170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.